Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CINDY E OWEN

Allopathic & Osteopathic Physicians Dermatology

NPI
1598803819
CMS profile
117868
Location
LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$2,410.66

70 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,449.80 66
Travel and Lodging $860.87 3
Education $99.99 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $1,556.01 9
Novartis Pharmaceuticals Corporation $284.47 20
Janssen Biotech, Inc. $254.37 21
Lilly USA, LLC $144.30 9
Amgen Inc. $67.04 4
AbbVie, Inc. $40.70 3
Ortho Dermatologics, a division of Bausch Health US, LLC $32.02 2
UCB, Inc. $17.50 1
DERMIRA, INC. $14.25 1

Page 1 of 2; records 1–50 of 70 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CINDY E OWEN

NPI 1598803819 · CMS profile ID 117868

Allopathic & Osteopathic Physicians / Dermatology

LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 70 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1598803819?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CINDY E OWEN, NPI 1598803819, CMS profile ID 117868. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 70 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598803819?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). CINDY E OWEN, NPI 1598803819, CMS profile ID 117868. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 70 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598803819?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
CINDY E OWEN, NPI 1598803819, CMS profile ID 117868, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 70 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1598803819?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

70 matching records · $2,410.66 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 70 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 70.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $14.5312/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 708393129 CMS
Amgen Inc. $13.0612/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662258797 CMS
Janssen Biotech, Inc. $13.1112/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 708393131 CMS
Janssen Biotech, Inc. $5.5112/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628231 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $15.5812/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684597153 CMS
Novartis Pharmaceuticals Corporation $16.9312/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659807053 CMS
UCB, Inc. $17.5011/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688331537 CMS
Janssen Biotech, Inc. $11.1511/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628227 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $16.4411/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684597151 CMS
Lilly USA, LLC $12.3011/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657741225 CMS
Janssen Biotech, Inc. $0.9511/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628225 CMS
Novartis Pharmaceuticals Corporation $13.0311/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659807049 CMS
PFIZER INC. $228.9410/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673854677 CMS
PFIZER INC. $665.8410/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673854679 CMS
PFIZER INC. $256.9710/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673854681 CMS
PFIZER INC. $374.9610/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673854683 CMS
Lilly USA, LLC $20.8210/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657748179 CMS
Novartis Pharmaceuticals Corporation $19.5410/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659806989 CMS
Janssen Biotech, Inc. $8.8909/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628221 CMS
Novartis Pharmaceuticals Corporation $16.1809/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659807041 CMS
Lilly USA, LLC $21.2609/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657730847 CMS
Novartis Pharmaceuticals Corporation $20.0009/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659807037 CMS
Janssen Biotech, Inc. $11.7008/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628211 CMS
Lilly USA, LLC $23.9208/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657748177 CMS
Janssen Biotech, Inc. $5.4208/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628199 CMS
AbbVie, Inc. $11.5708/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648273847 CMS
Janssen Biotech, Inc. $11.9307/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628193 CMS
Lilly USA, LLC $5.2407/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657734293 CMS
Novartis Pharmaceuticals Corporation $14.6907/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659807025 CMS
Amgen Inc. $13.8807/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662258795 CMS
Novartis Pharmaceuticals Corporation $21.2207/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659807021 CMS
DERMIRA, INC. $14.2507/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703887165 CMS
AbbVie, Inc. $18.1706/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648273889 CMS
Janssen Biotech, Inc. $99.9906/13/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628179 CMS
Janssen Biotech, Inc. $6.2406/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628169 CMS
Lilly USA, LLC $19.1306/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657755017 CMS
Janssen Biotech, Inc. $10.4806/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628161 CMS
Amgen Inc. $27.6705/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662258793 CMS
Janssen Biotech, Inc. $0.4505/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628157 CMS
Novartis Pharmaceuticals Corporation $13.4505/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659807029 CMS
Janssen Biotech, Inc. $1.0605/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628153 CMS
Janssen Biotech, Inc. $9.5904/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628141 CMS
Lilly USA, LLC $12.4804/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657748175 CMS
AbbVie, Inc. $10.9604/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648274075 CMS
Novartis Pharmaceuticals Corporation $11.0604/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659807033 CMS
Janssen Biotech, Inc. $12.5204/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628139 CMS
PFIZER INC. $11.3204/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673244427 CMS
Novartis Pharmaceuticals Corporation $12.8304/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659807013 CMS
Janssen Biotech, Inc. $0.9404/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658628131 CMS
Novartis Pharmaceuticals Corporation $8.8003/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659807011 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,410.66 70
PY2020 $4,329.13 26
PY2021 $1,014.27 67
PY2022 $1,019.13 72
PY2023 $883.07 50
PY2024 $1,269.36 78
PY2025 $1,140.98 54

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $848,779.58 205
PY2024 Principal investigator $465,404.25 284
PY2023 Principal investigator $512,761.61 145
PY2022 Recipient $8.00 1
PY2022 Principal investigator $318,333.10 76
PY2021 Recipient $579.11 2
PY2021 Principal investigator $303,603.63 109
PY2020 Recipient $5,811.05 7
PY2020 Principal investigator $509,738.55 72
PY2019 Recipient $47,562.83 13
PY2019 Principal investigator $1,244,974.63 84

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

97 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Amgen Inc. $1,547.00 12/24/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DS RESEARCH
Phase 2b study of Tezepelumab in Atopic Dermatitis. No dispute reported 06/30/2026 675778161
Principal investigator 1 AbbVie, Inc. $9,261.00 12/19/2019 Non-covered Recipient Entity
Scott Health Services, LLC
M15-999 No dispute reported 06/30/2026 647568217
Principal investigator 1 Genentech, Inc. $16,484.00 12/02/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
PHII OF MSTT1041A IN MOD SEVERE ATOPIC DERMATITITS No dispute reported 06/30/2026 708836475
Principal investigator 1 AbbVie, Inc. $4,159.75 11/27/2019 Non-covered Recipient Entity
Scott Health Services, LLC
M16-766 No dispute reported 06/30/2026 647568223
Principal investigator 1 PFIZER INC. $4,952.48 11/22/2019 Non-covered Recipient Entity
DS Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 671666047
Principal investigator 1 AbbVie, Inc. $6,054.00 11/21/2019 Non-covered Recipient Entity
Scott Health Services, LLC
M15-999 No dispute reported 06/30/2026 647568215
Recipient Eli Lilly and Company $2,385.84 11/21/2019 Covered Recipient Physician A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH PSORIASIS No dispute reported 06/30/2026 654281571
Recipient Eli Lilly and Company $2,464.20 11/21/2019 Covered Recipient Physician A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 654281831
Principal investigator 1 Eli Lilly and Company $200.00 11/18/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS RESEARCH
A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH PSORIASIS No dispute reported 06/30/2026 654289805
Principal investigator 1 AbbVie, Inc. $929.25 10/31/2019 Non-covered Recipient Entity
Scott Health Services, LLC
M16-766 No dispute reported 06/30/2026 647568219
Principal investigator 1 Incyte Corporation $66,583.62 10/22/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS PSC
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666516043
Principal investigator 1 AbbVie, Inc. $7,870.75 10/21/2019 Non-covered Recipient Entity
Scott Health Services, LLC
M15-999 No dispute reported 06/30/2026 647568209
Principal investigator 1 AbbVie, Inc. $11,256.00 10/02/2019 Non-covered Recipient Entity
Scott Health Services, LLC
M16-766 No dispute reported 06/30/2026 647568221
Principal investigator 1 Aclaris Therapeutics, Inc. $1,920.00 09/26/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700990215
Principal investigator 1 AbbVie, Inc. $13,639.00 09/19/2019 Non-covered Recipient Entity
Scott Health Services, LLC
M15-999 No dispute reported 06/30/2026 647568207
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $11,437.20 09/10/2019 Non-covered Recipient Entity
Associates In Dermatology Dispensar
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis No dispute reported 06/30/2026 639759343
Principal investigator 1 Perrigo Company plc $34,390.00 09/05/2019 Non-covered Recipient Entity
Scott Health Services, LLC
Bioequivalence study between Perrigo's product and Epiduo Forte Gel No dispute reported 06/30/2026 669993641
Principal investigator 1 AbbVie, Inc. $4,912.75 09/04/2019 Non-covered Recipient Entity
Scott Health Services, LLC
M15-999 No dispute reported 06/30/2026 647568205
Principal investigator 1 AbbVie, Inc. $12,851.50 08/29/2019 Non-covered Recipient Entity
Scott Health Services, LLC
M16-766 No dispute reported 06/30/2026 647568211
Principal investigator 1 PFIZER INC. $3,500.00 08/27/2019 Non-covered Recipient Entity
DS Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 671666043
Principal investigator 1 PFIZER INC. $3,500.00 08/27/2019 Non-covered Recipient Entity
DS Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 671666045
Principal investigator 1 Aclaris Therapeutics, Inc. $1,800.00 08/22/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700989911
Principal investigator 1 Amgen Inc. $13.12 08/22/2019 Non-covered Recipient Entity
DS RESEARCH
P3 KRd QW vs BIW Dosing Comparison in RRMM (A.R.R.O.W. 2) No dispute reported 06/30/2026 675785255
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,019.40 08/12/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES, LLC
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701426383
Principal investigator 1 Eli Lilly and Company $1,102.80 08/08/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 654296307
Recipient Bausch Health US, LLC $1,500.00 08/05/2019 Covered Recipient Physician A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 684338318
Recipient Bausch Health US, LLC $1,500.00 08/05/2019 Covered Recipient Physician A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 684338321
Principal investigator 1 AbbVie, Inc. $10,934.00 08/01/2019 Non-covered Recipient Entity
Scott Health Services, LLC
M16-766 No dispute reported 06/30/2026 647568213
Principal investigator 1 Aclaris Therapeutics, Inc. $3,120.00 08/01/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700989627
Principal investigator 1 Aclaris Therapeutics, Inc. $8,960.00 06/25/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700989219
Principal investigator 1 Amgen Inc. $11,396.00 06/25/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DS RESEARCH
Phase 2b study of Tezepelumab in Atopic Dermatitis. No dispute reported 06/30/2026 675792227
Principal investigator 1 PFIZER INC. $521.23 06/20/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS RESEARCH
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 671657791
Principal investigator 1 AbbVie, Inc. $20,984.25 06/13/2019 Non-covered Recipient Entity
Scott Health Services, LLC
M16-766 No dispute reported 06/30/2026 647568203
Principal investigator 1 Amgen Inc. $1,999.76 05/28/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
Phase 2b study of Tezepelumab in Atopic Dermatitis. No dispute reported 06/30/2026 675792203
Principal investigator 1 Aclaris Therapeutics, Inc. $15,760.00 05/23/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700988533
Principal investigator 1 Incyte Corporation $6,202.98 05/21/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS PSC
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666515959
Principal investigator 1 PFIZER INC. $691.28 05/07/2019 Non-covered Recipient Entity
Scott Health Services LLC dba DS Research
A PHASE 3B4 MULTICENTER RANDOMIZED ASSESSOR BLINDED VEHICLE AND ACTIVE TOPICAL CORTICOSTEROID AND CALCINEURIN INHIBITOR CONTROLLED PARALLEL GROUP STUDY OF THE EFFICACY SAFETY AND LOCAL TOLERABILITY OF CRISABOROLE OINTMENT 2 IN PEDIATRIC AND ADULT SUBJECTS AGES 2 YEARS AND OLDER WITH MILD TO MODERATE ATOPIC DERMATITIS No dispute reported 06/30/2026 671655231
Principal investigator 1 AbbVie, Inc. $9,001.50 05/03/2019 Non-covered Recipient Entity
Scott Health Services, LLC
M16-766 No dispute reported 06/30/2026 647568201
Principal investigator 1 Aclaris Therapeutics, Inc. $23,050.00 04/25/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700988153
Principal investigator 1 Amgen Inc. $947.06 04/25/2019 Non-covered Recipient Entity
DS RESEARCH KENTUCKY
Phase 2b study of Tezepelumab in Atopic Dermatitis. No dispute reported 06/30/2026 675785261
Principal investigator 1 Eli Lilly and Company $23.57 04/25/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS RESEARCH
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 654295643
Principal investigator 1 Perrigo Company plc $19,965.00 04/23/2019 Non-covered Recipient Entity
Scott Health Services, LLC
Bioequivalence study between Perrigo's product and Epiduo Forte Gel No dispute reported 06/30/2026 669976999
Principal investigator 1 Perrigo Company plc $6,926.30 04/16/2019 Non-covered Recipient Entity
Scott Health Services, LLC
Bioequivalence study between Perrigo's product and Epiduo Forte Gel No dispute reported 06/30/2026 669976959
Principal investigator 1 Aclaris Therapeutics, Inc. $3,250.00 04/09/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700987887
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $3,000.00 04/08/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES, LLC
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701426331
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $4,640.00 04/08/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES, LLC
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701426333
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $500.00 04/08/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES, LLC
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701426349
Principal investigator 1 Aclaris Therapeutics, Inc. $5,000.00 04/05/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700987859
Principal investigator 1 AbbVie, Inc. $11,411.25 04/03/2019 Non-covered Recipient Entity
Scott Health Services, LLC
M16-766 No dispute reported 06/30/2026 647568231
Principal investigator 1 PFIZER INC. $322.30 03/22/2019 Non-covered Recipient Entity
Scott Health Services LLC dba DS Research
A PHASE 3B4 MULTICENTER RANDOMIZED ASSESSOR BLINDED VEHICLE AND ACTIVE TOPICAL CORTICOSTEROID AND CALCINEURIN INHIBITOR CONTROLLED PARALLEL GROUP STUDY OF THE EFFICACY SAFETY AND LOCAL TOLERABILITY OF CRISABOROLE OINTMENT 2 IN PEDIATRIC AND ADULT SUBJECTS AGES 2 YEARS AND OLDER WITH MILD TO MODERATE ATOPIC DERMATITIS No dispute reported 06/30/2026 671657993
Principal investigator 1 Aclaris Therapeutics, Inc. $9,970.00 03/19/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700987615
Principal investigator 1 Eli Lilly and Company $41,838.00 03/19/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 654297299
Recipient Eli Lilly and Company $17.44 03/14/2019 Covered Recipient Physician ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 654281829
Principal investigator 1 Aclaris Therapeutics, Inc. $17,620.00 03/05/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700987321
Principal investigator 1 Eli Lilly and Company $33,694.00 03/05/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 654294375
Principal investigator 1 AbbVie, Inc. $11,758.00 03/01/2019 Non-covered Recipient Entity
Scott Health Services, LLC
M16-766 No dispute reported 06/30/2026 647568227
Principal investigator 1 Incyte Corporation $1,000.00 03/01/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS PSC
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666515929
Principal investigator 1 Incyte Corporation $1,400.00 03/01/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS PSC
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666515931
Principal investigator 1 Incyte Corporation $481.10 03/01/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS PSC
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666516089
Principal investigator 1 Incyte Corporation $96.24 03/01/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS PSC
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666516091
Principal investigator 1 Incyte Corporation $292.70 03/01/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS PSC
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666516095
Principal investigator 1 Incyte Corporation $103.36 03/01/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS PSC
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666516099
Principal investigator 1 Incyte Corporation $124.40 03/01/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS PSC
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666516105
Principal investigator 1 Incyte Corporation $216.13 03/01/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS PSC
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666516111
Principal investigator 1 Incyte Corporation $108.03 03/01/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS PSC
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 666516119
Principal investigator 1 Aclaris Therapeutics, Inc. $3,250.00 02/26/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700986959
Principal investigator 1 Aclaris Therapeutics, Inc. $5,000.00 02/26/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700986991
Recipient Eli Lilly and Company $8,190.00 02/26/2019 Covered Recipient Physician A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 654281631
Recipient Eli Lilly and Company $2,848.00 02/26/2019 Covered Recipient Physician A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654281717
Recipient Eli Lilly and Company $1,378.00 02/26/2019 Covered Recipient Physician A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 No dispute reported 06/30/2026 654281783
Recipient Eli Lilly and Company $862.10 02/25/2019 Covered Recipient Physician A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 No dispute reported 06/30/2026 654281523
Principal investigator 1 Eli Lilly and Company $22.36 02/21/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS RESEARCH
A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654292753
Principal investigator 1 PFIZER INC. $322.30 02/19/2019 Non-covered Recipient Entity
Scott Health Services LLC dba DS Research
A PHASE 3B4 MULTICENTER RANDOMIZED ASSESSOR BLINDED VEHICLE AND ACTIVE TOPICAL CORTICOSTEROID AND CALCINEURIN INHIBITOR CONTROLLED PARALLEL GROUP STUDY OF THE EFFICACY SAFETY AND LOCAL TOLERABILITY OF CRISABOROLE OINTMENT 2 IN PEDIATRIC AND ADULT SUBJECTS AGES 2 YEARS AND OLDER WITH MILD TO MODERATE ATOPIC DERMATITIS No dispute reported 06/30/2026 671657629
Principal investigator 1 Eli Lilly and Company $38,021.00 02/12/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 654291471
Principal investigator 1 Eli Lilly and Company $34,972.00 02/12/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 No dispute reported 06/30/2026 654292533
Principal investigator 1 Eli Lilly and Company $117,312.00 02/12/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654293407
Principal investigator 1 Perrigo Company plc $16,150.00 02/08/2019 Non-covered Recipient Entity
Scott Health Services, LLC
Bioequivalence study between Perrigo's product and Epiduo Forte Gel No dispute reported 06/30/2026 669953219
Principal investigator 1 Amgen Inc. $2,672.50 02/05/2019 Non-covered Recipient Entity
DS RESEARCH
Phase 2b study of Tezepelumab in Atopic Dermatitis. No dispute reported 06/30/2026 675785259
Principal investigator 1 Eli Lilly and Company $128,472.00 02/05/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 654297297
Principal investigator 1 PFIZER INC. $951.29 02/05/2019 Non-covered Recipient Entity
Scott Health Services LLC dba DS Research
A PHASE 3B4 MULTICENTER RANDOMIZED ASSESSOR BLINDED VEHICLE AND ACTIVE TOPICAL CORTICOSTEROID AND CALCINEURIN INHIBITOR CONTROLLED PARALLEL GROUP STUDY OF THE EFFICACY SAFETY AND LOCAL TOLERABILITY OF CRISABOROLE OINTMENT 2 IN PEDIATRIC AND ADULT SUBJECTS AGES 2 YEARS AND OLDER WITH MILD TO MODERATE ATOPIC DERMATITIS No dispute reported 06/30/2026 671658027
Principal investigator 1 AbbVie, Inc. $12,748.25 02/04/2019 Non-covered Recipient Entity
Scott Health Services, LLC
M16-766 No dispute reported 06/30/2026 647568225
Principal investigator 1 Amgen Inc. $2,755.85 01/28/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
Phase 2b study of Tezepelumab in Atopic Dermatitis. No dispute reported 06/30/2026 675792211
Recipient Eli Lilly and Company $870.25 01/28/2019 Covered Recipient Physician A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 654281833
Principal investigator 1 Eli Lilly and Company $1,713.85 01/28/2019 Non-covered Recipient Entity
ARTHRITIS CONSULTANTS INC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 654287983
Principal investigator 1 Eli Lilly and Company $793.33 01/28/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 654291819
Principal investigator 1 Eli Lilly and Company $802.80 01/28/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS RESEARCH
A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 654295645
Principal investigator 1 Aclaris Therapeutics, Inc. $19,220.00 01/22/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700986713
Principal investigator 1 PFIZER INC. $1,543.71 01/19/2019 Non-covered Recipient Entity
Scott Health Services LLC dba DS Research
A PHASE 3B4 MULTICENTER RANDOMIZED ASSESSOR BLINDED VEHICLE AND ACTIVE TOPICAL CORTICOSTEROID AND CALCINEURIN INHIBITOR CONTROLLED PARALLEL GROUP STUDY OF THE EFFICACY SAFETY AND LOCAL TOLERABILITY OF CRISABOROLE OINTMENT 2 IN PEDIATRIC AND ADULT SUBJECTS AGES 2 YEARS AND OLDER WITH MILD TO MODERATE ATOPIC DERMATITIS No dispute reported 06/30/2026 671655075
Recipient Eli Lilly and Company $5,382.00 01/15/2019 Covered Recipient Physician A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 654281525
Recipient Eli Lilly and Company $12,180.00 01/15/2019 Covered Recipient Physician ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 654281921
Recipient Eli Lilly and Company $7,985.00 01/08/2019 Covered Recipient Physician A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 654281573
Principal investigator 1 AbbVie, Inc. $10,857.50 01/07/2019 Non-covered Recipient Entity
Scott Health Services, LLC
M16-766 No dispute reported 06/30/2026 647568229
Principal investigator 1 PFIZER INC. $2,485.45 01/04/2019 Non-covered Recipient Entity
Scott Health Services LLC dba DS Research
A PHASE 3B4 MULTICENTER RANDOMIZED ASSESSOR BLINDED VEHICLE AND ACTIVE TOPICAL CORTICOSTEROID AND CALCINEURIN INHIBITOR CONTROLLED PARALLEL GROUP STUDY OF THE EFFICACY SAFETY AND LOCAL TOLERABILITY OF CRISABOROLE OINTMENT 2 IN PEDIATRIC AND ADULT SUBJECTS AGES 2 YEARS AND OLDER WITH MILD TO MODERATE ATOPIC DERMATITIS No dispute reported 06/30/2026 671654931
Principal investigator 1 Aclaris Therapeutics, Inc. $5,810.00 01/03/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700986431
Principal investigator 1 Celgene Corporation $15,155.00 01/03/2019 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A Phase 3, Multi-Center, Randomized, Place-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004 in subjects with Moderate to Sever Plaque Psoriasis of the Scap) (CC-10004-SPSO-001) No dispute reported 06/30/2026 675418873
Principal investigator 1 Eli Lilly and Company $799.94 01/03/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 654293709
Principal investigator 1 Novartis Pharmaceuticals Corporation $316,451.44 01/02/2019 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS RESESARCH
A RANDOMIZED DOUBLE BLIND MULTICENTER STUDY ASSESSING SHORT 16 WEEKS AND LONG TERM EFFICACY UP TO 1 YEAR SAFETY AND TOLERABILITY OF SUBCUTANEOUS SECUKINUMAB IN SUBJECTS OF BODY WEIGHT 90 KG OR HIGHER WITH MODERATE TO SEVERE CHRONIC PLAQUE TYPE PSORIASIS No dispute reported 06/30/2026 640715117